CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 101 enrolled
Drug / intervention
zoster vaccine live (ZOSTAVAX™) +1 morebiological
Likely dose
zoster vaccine live (ZOSTAVAX™) 0.65 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00322231
NCT00322231Phase 3Completed
CompareCT.gov

A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Subjects With a History of Herpes Zoster

Merck Sharp & Dohme LLC·interventional·Posted May 5, 2006·Updated Jan 26, 2015

In Brief

A Phase 3 clinical trial evaluating zoster vaccine live (ZOSTAVAX™) and Comparator: Placebo for Herpes Zoster. Completed, enrolled 101 participants.

Detailed Summary

The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 5, 2006
Enrollment StartMay 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.2 years ago

Interventions

zoster vaccine live (ZOSTAVAX™)biological

1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live

Comparator: Placebobiological

1 dose 0.65 mL/dose subcutaneous injection of placebo.